

Supplement Article

**13-ICML SATELLITE SYMPOSIA PROGRAMS
(updated on May 9, 2015)**

Tuesday, June 16, from 12:00 to 14:00 (room B I)

AMGEN (EUROPE) GmbH

**NOVEL APPROACHES TO LYMPHOMA AND LEUKAEMIA: ENGAGING THE T CELL
WITH BISPECIFIC ANTIBODY CONSTRUCTS**

Chair: M. Ghilmini, Bellinzona (Switzerland)

WELCOME

M. Ghilmini, Bellinzona (Switzerland)

IMMUNOTHERAPY IN HAEMATOLOGICAL MALIGNANCIES

M. Ghilmini, Bellinzona (Switzerland)

HARNESSING THE IMMUNE SYSTEM WITH BITE ANTIBODIES

M. Klinger, Munich (Germany)

EMERGING CLINICAL DATA WITH T-CELL-ENGAGING IMMUNOTHERAPIES

in NHL: A. Viardot, Ulm (Germany)

in ALL: M. Topp, Wuerzburg (Germany)

SUMMARY AND CLOSE

M. Ghilmini, Bellinzona (Switzerland)

Tuesday, June 16, from 15:30 to 17:30 (room B I)

NOVARTIS ONCOLOGY

MORE EVIDENCE, MORE OPTIONS: FIRST-LINE TREATMENT OF CLL

Chair: K. Stamatopoulos, Thessaloniki (Greece)

CHAIR'S WELCOME AND INTRODUCTION

K. Stamatopoulos, Thessaloniki (Greece)

FIRST-LINE THERAPY OF LESS FIT PATIENTS: OFATUMUMAB PLUS CHLORAMBUCIL

M. Montillo, Milan (Italy)

FIRST-LINE THERAPY OF LESS FIT PATIENTS: BENDAMUSTINE IN COMBINATION WITH ANTI-CD20 ANTIBODIES

F. Offner, Gent (Belgium)

NEW COMBINATIONS, INNOVATIVE SEQUENCING, TAILORED TREATMENTS. WHAT DOES THE FUTURE HOLD FOR CLL PATIENTS?

S. Stilgenbauer, Ulm (Germany)

PANEL DISCUSSION

All speakers

Tuesday, June 16, from 15:30 to 17:30 (room B II)

CTI LIFE SCIENCES LIMITED AND SERVIER

CHANGING EXPECTATIONS IN THE TREATMENT OF RELAPSED AND REFRACTORY AGGRESSIVE NHL

Chair: M. Ghielmini, Bellinzona (Switzerland)

GUIDELINES AND CHALLENGES IN MANAGING RELAPSED AND REFRACTORY aNHL

M. Ghielmini, Bellinzona (Switzerland)

CLINICAL IMPLICATIONS OF THE NOVEL MECHANISM OF ACTION OF PIXANTRONE

G. Minotti, Rome (Italy)

TREATMENT OPTIONS FOR THE MANAGEMENT OF RELAPSED AND REFRACTORY DLBCL

A. Davies, Southampton (UK)

PRELIMINARY RESULTS WITH A NOVEL REGIMEN (PRE-BEN) IN LATE STAGE, REFRACTORY HIGH-GRADE NHL: THE NORDIC EXPERIENCE

F. d'Amore, Aarhus (Denmark)

Tuesday, June 16, from 19:00 to 21:00 (room A)

BRISTOL-MYERS SQUIBB

IMMUNO-ONCOLOGY: A NEW ERA IN HEMATOLOGY TREATMENT?

EMERGING RESEARCH IN LYMPHOMA AND MYELOMA

Chair: A. Engert, Cologne (Germany)

WELCOME AND INTRODUCTION

A. Engert, Cologne (Germany)

WHY IMMUNO-ONCOLOGY IN HEMATOLOGY?

A. Engert, Cologne (Germany)

POTENTIAL ROLE OF I-O IN MYELOMA

M. Mohty, Paris (France)

A NEW ERA IN MYELOMA?

K. Weisel, Tuebingen (Germany)

POTENTIAL ROLE OF I-O IN LYMPHOMA

S.M. Ansell, Rochester, MN (USA)

A NEW ERA IN LYMPHOMA?

P.L. Zinzani, Bologna (Italy)

QUESTION AND ANSWER

Full panel

Tuesday, June 16, from 19:00 to 21:00 (room B I)

BAYER HEALTHCARE PHARMACEUTICALS, INC.

THE EVOLVING THERAPEUTIC POTENTIAL OF PI3K INHIBITORS IN RELAPSED OR REFRACTORY NON-HODGKIN'S LYMPHOMA

Chair: M. Ghielmini, Bellinzona (Switzerland)

WELCOME, INTRODUCTION, AND CASE STUDY ON THE CURRENT STANDARD OF CARE IN RELAPSED OR REFRACTORY INDOLENT NHL

M. Ghielmini, Bellinzona (Switzerland)

MECHANISMS OF DRUG RESISTANCE IN MCL AND POTENTIAL MITIGATION STRATEGIES

S. Chen-Kiang, New York, NY (USA)

THE LANDSCAPE OF PI3K AND BCR SIGNALING INHIBITORS IN CLINICAL DEVELOPMENT FOR THE TREATMENT OF NHL

J.P. Leonard, New York, NY (USA)

CLINICAL ACTIVITY OF COPANLISIB IN NHL

M. Dreyling, Munich (Germany)

Q&A

Panel

CLOSING REMARKS

M. Ghielmini, Bellinzona (Switzerland)

Tuesday, June 16, from 19:00 to 21:00 (room B II)

TAKEDA ONCOLOGY, SEATTLE GENETICS, INC, THE LEUKEMIA LYMPHOMA SOCIETY AND MEDICOM WORLDWIDE, INC.

CONTEMPORARY THERAPY FOR HODGKIN LYMPHOMA: WHERE ARE WE NOW?

Chair: F. Cavalli, Bellinzona (Switzerland)

WELCOME, INTRODUCTION, OVERVIEW

F. Cavalli, Bellinzona (Switzerland)

CURRENT AND EMERGING STRATEGIES IN FRONT LINE TREATMENT

T. Illidge, Manchester (UK)

RELAPSED REFRACTORY HODGKIN LYMPHOMA: CHANGING TREATMENT PARADIGMS?

P. Borchmann, Cologne (Germany)

WHERE DO WE GO FROM HERE: CONCLUSIONS AND WRAP UP

F. Cavalli, Bellinzona (Switzerland)

Wednesday, June 17, from 19:00 to 21:00 (room A)

JANSSEN PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON

CHALLENGING THE PARADIGMS IN B-CELL MALIGNANCIES

Co-Chairs: M. Dreyling, Munich (Germany) and S. Rule, Plymouth (UK)

WELCOME AND INTRODUCTION

M. Dreyling, Munich (Germany)

LEVERAGING THE B-CELL SIGNALLING PATHWAYS

M. Dreyling, Munich (Germany)

APPLYING BIOLOGICAL INSIGHTS TO THE CLINICAL MANAGEMENT OF MANTLE CELL LYMPHOMA

M.L. Wang, Houston, TX (USA)

PANEL DISCUSSION

All

INTEGRATING NOVEL THERAPIES INTO THE PRACTICAL MANAGEMENT OF PATIENTS WITH WALDENSTRÖM'S MACROGLOBULINEMIA

S. Treon, Boston, MA (USA)

THE BIOLOGIC BASIS FOR IMPROVED CLINICAL MANAGEMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA

S. Stilgenbauer, Ulm (Germany)

PANEL DISCUSSION

All

Wednesday, June 17, from 19:00 to 21:00 (room B)

GILEAD SCIENCES EUROPE, LTD.

NEW OPTIONS AND EVOLVING STRATEGIES IN THE MANAGEMENT OF HEMATOLOGICAL MALIGNANCIES

Co-Chairs: M. Hallek, Cologne (Germany) and G. Salles, Lyon (France)

INTRODUCTION: A REVIEW OF THE CURRENT LANDSCAPE IN HEMATOLOGICAL MALIGNANCIES

G. Salles, Lyon (France)

NOVEL TARGETED THERAPIES IN DIFFICULT-TO-TREAT CLL

M. Hallek, Cologne (Germany)

CRITICAL CASES IN CLL—APPLYING THE LATEST KNOWLEDGE TO SPECIFIC SCENARIOS

B. Eichhorst, Cologne (Germany)

TREATMENT STRATEGIES FOR PROLONGED CARE—OPTIONS AND SEQUENCING IN RELAPSED iNHL

G. Salles, Lyon (France)

CRITICAL CASES IN iNHL—APPLYING THE LATEST KNOWLEDGE TO SPECIFIC SCENARIOS

A. Davies, Southampton (UK)

LOOKING FORWARD: THE EVOLVING TREATMENT PARADIGM IN CLL AND FL

M. Dreyling, Munich (Germany)

OPEN Q&A BASED ON DISCUSSIONS FROM THE PRESENTATIONS

All, led by Co-Chairs

SUMMARY AND CLOSE

M. Hallek, Cologne (Germany)

Thursday, June 18, from 19:00 to 21:00 (room A)

CELGENE CORPORATION

IMMUNE-BASED STRATEGIES TOWARDS ADVANCING THE TREATMENT OF B-CELL MALIGNANCIES

Chair: F. Cavalli, Bellinzona (Switzerland)

WELCOME AND INTRODUCTION

F. Cavalli, Bellinzona (Switzerland)

THE QUEST FOR ENDPOINTS IN GUIDING TREATMENT DECISIONS IN FOLLICULAR LYMPHOMA

N. Fowler, Houston, TX (USA)

NEW APPROACHES TO THE TREATMENT OF FOLLICULAR LYMPHOMA

B.D. Cheson, Washington, DC (USA)

OPTIMIZING TREATMENT OF RELAPSED AND/OR REFRACTORY MANTLE CELL LYMPHOMA

M. Trněný, Prague (Czech Republic)

IMPROVING ON FRONTLINE OUTCOMES IN DIFFUSE LARGE B-CELL LYMPHOMA

U. Vitolo, Turin (Italy)

ADVANCEMENT IN OUR UNDERSTANDING OF IMMUNOMODULATING AGENTS IN B-CELL MALIGNANCIES

J.G. Gribben, London (UK)

CLOSING REMARKS

F. Cavalli, Bellinzona (Switzerland)

Immune-based strategies towards advancing the treatment of B-cell malignancies

B-cell lymphomas make up approximately 85% of non-Hodgkin lymphomas (NHLs) and, despite the emergence of novel therapies, optimization of treatment for patients with lymphoma still requires further attention [1–3]. The development of novel therapies will help fulfil the unmet needs of patients with NHL, which include treatment toxicities, frequent relapses, and emergence of therapeutic resistance.

Several pathways that play key roles in the development of B-cell malignancies have been identified [4]. We are also gaining an increasing understanding of how non-malignant effector cells in the immune microenvironment contribute to tumor cell survival and proliferation, and the emergence of therapeutic resistance. These new insights, combined with streamlined advances in medicinal chemistry, have moved treatment approaches away from traditional chemotherapy. A deeper understanding of tumorigenic mechanisms has resulted in the development of non-chemotoxic treatments. Such treatments include the use of tyrosine kinase inhibitors (TKIs), which specifically inhibit the deregulated activity of individual molecules in the signal transduction cascade, as well as immunomodulatory agents and checkpoint inhibitors. Immune-based approaches alter microenvironmental mechanisms, thus preventing tumors from developing immune tolerance. Several novel therapeutic targets are being investigated; these include inhibitors of the B-cell receptor signaling pathways, the PI3K/mTOR/Akt pathway, histone deacetylases, BCL-2, the proteasome, PD-1 and PD-L1, and the tumor immune microenvironment [4]. Many of the new agents show excellent toxicity profiles, and combining these novel therapies may result in a higher quality of response and potentially significant improvement in survival outcomes for NHL patients [4–6].

Advances are being made in understanding how non-cytotoxic agents act against various B-cell malignancies. Progress in unraveling the underlying biology is setting the stage for the development of novel treatment paradigms with the aim of improving on current standards of care. New treatment paradigms will have to address how novel agents can be integrated into existing modalities. In short, the increased number of potential therapeutic options warrants the need to re-evaluate the utility of current treatment guidelines and clinical endpoints in relation to the optimization of patient outcomes.

References

1. Ghielmini M, Vitolo U, Kimby E, *et al.* ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). *Ann Oncol* 2013; **24**: 561–76.
2. Dreyling M, Ghielmini M, Marcus R, Salles G, Vitolo U. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2014; **25**(Suppl 3): iii76–82.
3. Dreyling M, Geisler C, Hermine O, *et al.* Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2014; **25**(Suppl 3): iii83–92.
4. Fowler N, Oki Y. Developing novel strategies to target B-cell malignancies. *Am Soc Clin Oncol Educ Book* 2013: 366–72.
5. Trněný M, Lamy T, Walewski J, *et al.* Phase II randomized, multicenter study of lenalidomide vs best investigator's choice in relapsed/refractory MCL: results of the MCL-002 (SPRINT) study. *Blood* 2014;**124**:abstract 626.
6. Wang ML, Rule S, Martin P, *et al.* Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. *N Engl J Med* 2013; **369**: 507–16.

Thursday, June 18, from 19:00 to 21:00 (room B)

MUNDIPHARMA ONCOLOGY

CLL AND FOLLICULAR NHL: CRITICAL REVIEW OF THE CURRENT GUIDELINES AND FUTURE PERSPECTIVES

Co-chairs: J.G. Gribben, London (UK) and M. Ghielmini, Bellinzona (Switzerland)

GERMAN PRACTICES IN CLL

C. Wendtner, Munich (Germany)

FRENCH PRACTICES IN CLL

O. Tournilhac, Clermont Ferrand (France)

UK PRACTICES IN FOLLICULAR NHL

A. Davies, Southampton (UK)

SWISS PRACTICES IN FOLLICULAR NHL

M. Ghielmini, Bellinzona (Switzerland)

Friday, June 19, from 18:45 to 19:45 (room A)

ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND—IOSI

Supported by an unrestricted educational grant by GILEAD SCIENCES EUROPE, LTD.

THE BIG DEBATE: SHOULD WE ALWAYS AIM AT MINIMAL RESIDUAL DISEASE ERADICATION?

Chair: M. Ghilmini, Bellinzona (Switzerland)

CLL —YES: J.G. Gribben, London (UK) vs
—NO: S. Stilgenbauer, Ulm (Germany)

MCL —YES: M. Dreyling, Munich (Germany) vs
—NO: J.P. Leonard, New York, NY (USA)

MM —YES: M. Cavo, Bologna (Italy) vs
—NO: S.V. Rajkumar, Rochester, MN (USA)